Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>JPM Initiates Coverage on HANSOH PHARMA w/ Rating Overweight, TP HKD43
Recommend 8 Positive 9 Negative 5 |
||||
|
||||
|
JPMorgan has released a research report initiating coverage on HANSOH PHARMA (03692.HK) with an Overweight rating and a target price of HKD43 based on discounted cash flow analysis. According to the report, HANSOH PHARMA has transformed into an innovation-driven leader in recent years, with the contribution from innovative product sales surging from 18% in 2020 to 77% in 2024, achieving a 57% CAGR. The broker believes HANSOH PHARMA is one of the most advantaged companies among Chinese biopharmaceutical firms and is poised to benefit from the trend of licensing collaborations. Among the pharma companies under its coverage, JPMorgan prefers HANSOH PHARMA over HENGRUI PHARMA (01276.HK) (600276.SH) (rated Neutral), as the former offers a more attractive risk-reward at current levels (current valuation equates to a forecasted 2026 P/E ratio of 36 times, compared to HENGRUI PHARMA's A-shares and H-shares at 49 times and 56 times). AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
